Evaluation of the impact of enhanced recovery after surgery protocol implementation on maternal outcomes following elective cesarean delivery

BackgroundDespite significant improvements in outcomes following non-obstetric surgery with implementation of enhanced recovery after surgery (ERAS) protocols, development of these protocols for cesarean delivery is lacking. We evaluated implementation of an ERAS protocol for patients undergoing elective cesarean delivery, specifically the effect on opioid consumption, pain scores and length of stay as well as complications and re-admissions.MethodsAn ERAS protocol was developed and implemented for women undergoing elective cesarean delivery. The protocol construction included specific evidence-based items applicable to peripartum management and these were grouped into the three major phases of patient care: antepartum, intrapartum and postpartum. A before-and-after study design was used to compare maternal outcomes. To account for confounders between groups, a propensity matched scoring analysis was used. The primary outcome was postpartum opioid use in mg-morphine equivalents (MMEQ).ResultsWe included 357 (n=196 before; n=161 after) women who underwent elective cesarean delivery. A significant difference in opioid consumption (28.4 ± 24.1 vs 46.1 ± 37.0 MMEQ, P <0.001) and in per-day postoperative opioid consumption (10.9 ± 8.7 vs 15.1 ± 10.3 MMEQ, P <0.001), lower peak pain scores (7 [5–9] vs 8 [7–9], P=0.007) and a shorter hospital length of stay (2.5 ± 0.5 vs 2.9 ± 1.2 days, P <0.001) were found after the introduction of the ERAS protocol.ConclusionsImplementation of ERAS protocols for elective cesarean delivery is associated with significant improvements in analgesic and recovery outcomes. These improvements in quality of care suggest ERAS protocols should be considered for elective cesarean delivery.     

Intra-operative ketorolac 15 mg versus 30 mg for analgesia following cesarean delivery: a retrospective study

BackgroundKetorolac is a nonsteroidal anti-inflammatory drug used as part of multimodal analgesia in women undergoing cesarean delivery. The lowest effective dose of ketorolac that best optimizes analgesia without increasing side effects is unclear. We performed this retrospective study to compare the analgesic efficacy of 15 mg or 30 mg ketorolac administered intra-operatively to our obstetric population.MethodsWe included patients who underwent cesarean delivery under neuraxial anesthesia and received 15 mg or 30 mg of ketorolac intra-operatively. Our multimodal analgesic regimen is standardized and includes 150 µg spinal or 3 mg epidural morphine, 975 mg rectal acetaminophen, and 15–30 mg intravenous ketorolac within 15 min of surgery completion. The primary outcome was opioid use in the first 6 h after surgery. Secondary outcomes were opioid use at 24 and 48 h, opioid dose, pain scores, breastfeeding, postoperative serum creatinine and need for rescue anti-emetics.ResultsOne-thousand-three-hundred and forty-nine patients were analyzed (15 mg ketorolac n=999; 30 mg n=350). There was no difference between the two groups in patient demographics or intra-operative characteristics. There was no significant difference between groups for opioid use at 6 h after surgery (50.3% vs 52.0%, odds ratio [95% confidence interval] 1.13 [0.87 to 1.47]). There were also no significant differences between the groups for secondary outcomes.ConclusionsThere was no difference in opioid use between patients receiving either a 15 mg or a 30 mg dose of ketorolac given intra-operatively for postoperative analgesia following cesarean delivery.     

Analgesic requirements and postoperative recovery after scheduled compared to unplanned cesarean delivery: a retrospective chart review

BackgroundStudies examining the effects of various analgesics and anesthetics on postoperative pain following cesarean delivery conventionally use the scheduled cesarean population. This study compares postoperative analgesic requirements and recovery profiles in women undergoing scheduled cesarean compared to unplanned cesarean delivery following labor. We postulated that unplanned cesarean deliveries may increase postoperative analgesic requirements.MethodsWe conducted a retrospective chart review of 200 cesarean deliveries at Lucile Packard Children’s Hospital, California. We examined the records of 100 patients who underwent scheduled cesarean delivery under spinal anesthesia (hyperbaric bupivacaine 12 mg with intrathecal fentanyl 10 μg and morphine 200 μg) and 100 patients that following a trail of labor required unplanned cesarean under epidural anesthesia (10–25 mL 2% lidocaine top-up with epidural morphine 4 mg after clamping of the umbilical cord). We recorded pain scores, analgesic consumption, time to first analgesic request, side effects, and length of hospital stay.ResultsWe found no differences in postoperative pain scores and analgesic consumption between scheduled and unplanned cesarean deliveries for up to five days postoperatively. There were no differences in treatment of side effects such as nausea, vomiting, or pruritus (P > 0.05).ConclusionThe results indicate that women experience similar pain and analgesic requirements after scheduled compared to unplanned cesarean delivery. This suggests that the non-scheduled cesarean population may be a suitable pain model to study pain management strategies; and that alterations in pain management are not necessary for the unplanned cesarean delivery population.     

Systemic adjunct analgesics for cesarean delivery: a narrative review

It is critical to adequately treat postoperative cesarean delivery pain. The use of parenteral or neuraxial opioids has been a mainstay, but opioids have side effects that can be troubling and the opioid crisis in the United States has highlighted the necessity to utilize analgesics other than opioids. Other analgesic options include neuraxial analgesics, nerve blocks such as the transversus abdominis plane block, and non-opioid parenteral and oral medications. The goal of this article is to review non-opioid systemic analgesic adjuncts following cesarean delivery, focusing on their efficacy and side effects as well as their impact on reduction of opioid requirements after surgery.     

Impact of intra-operative dexamethasone after scheduled cesarean delivery: a retrospective study

BackgroundDexamethasone is an effective analgesic and anti-emetic in patients undergoing many surgical procedures but its effects on pain after cesarean delivery are poorly studied. The aim of this study was to evaluate if routine intra-operative administration of dexamethasone improved analgesia and decreased postoperative nausea and vomiting after scheduled cesarean delivery.MethodsElectronic medical record data for scheduled cesarean deliveries performed under neuraxial anesthesia, before and after a practice change that introduced the routine use of intravenous dexamethasone 4 mg, were obtained. Patients were analyzed based on whether they received routine care (n=182) or also received dexamethasone (n=187). The primary outcome was time to first opioid use. Secondary outcomes included postoperative opioid consumption, pain scores, incidence and treatment of postoperative nausea and vomiting, satisfaction and length of stay.ResultsThere was no significant difference between groups in median time to first postoperative opioid administration (15.8 [3.4–48.0] h routine care vs 14.7 [3.2–38.8] h routine care plus dexamethasone, P=0.08). There were no significant differences in any secondary outcomes.ConclusionsThis impact study involving more than 360 patients suggests that routine administration of intra-operative intravenous dexamethasone 4 mg does not provide additional analgesic benefit after scheduled cesarean delivery, in the context of a multimodal postoperative analgesic regimen. Studies are required to determine if a larger dose or repeated administration influence postoperative analgesia or side effects, or whether certain subsets of patients may benefit.     

Quadratus lumborum block for postoperative analgesia after cesarean delivery: a systematic review and meta-analysis

BackgroundQuadratus lumborum block (QLB) can reduce pain and opioid consumption after cesarean delivery. This systematic review investigated the effectiveness of QLB in reducing postoperative opioid use and its effect on pain scores compared with other analgesic methods after cesarean delivery.MethodsSix medical databases were searched from their inception to August 2019. Trials were eligible if parturients underwent cesarean delivery under spinal anesthesia (not epidural or general anesthesia). The primary outcome was postoperative opioid consumption during the first 24 and 48 h. Secondary outcomes included pain scores, patient satisfaction, and side effects. The risk of bias was assessed using the Cochrane tool. Where possible, meta-analytic techniques were used to synthesize data, presented as mean difference with 95% confidence interval (CI).ResultsTwelve studies involving 904 patients were identified and analyzed. Opioid (intravenous morphine) consumption was significantly reduced with QLB when compared with placebo or no block during the first 24 h by 14.1 mg, (95% CI −20.8 to −7.5 mg) and 48 h by 20.8 mg, (95% CI −33.1 to −8.5 mg). Additionally, QLB significantly reduced 12-h pain scores at rest and during movement. However, this difference disappeared at 24 and 48 h. There was insufficient evidence regarding postoperative opioid use or pain scores with the use of QLB compared to intrathecal morphine.ConclusionsThe review findings show the superior analgesic effect of QLB when compared with systemic opioids in reducing postoperative opioid consumption, when intrathecal morphine is not administered.     

Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study

Although nonsteroidal antiinflammatory drugs (NSAIDs) improve postoperative pain relief after cesarean delivery, they carry potential side effects (e.g., bleeding). Perioperative cyclooxygenase (COX)-2 inhibitors show similar analgesic efficacy to nonsteroidal antiinflammatory drugs in many surgical models but have not been studied after cesarean delivery. We designed this randomized double-blind study to determine the analgesic efficacy and opioid-sparing effects of valdecoxib after cesarean delivery. Healthy patients undergoing elective cesarean delivery under spinal anesthesia were randomized to receive oral valdecoxib 20 mg or placebo every 12 h for 72 h postoperatively. As a result of cyclooxygenase-2 inhibitors safety concerns that became apparent during this study, the study was terminated early after evaluating 48 patients. We found no differences in total analgesic consumption between the valdecoxib and placebo groups (121 +/- 70 versus 143 +/- 77 morphine mg-equivalents, respectively; P = 0.26). Pain at rest and during activity were similar between the groups despite adequate post hoc power to have detected a clinically significant difference. There were also no differences in IV morphine requirements, time to first analgesic request, patient satisfaction, side effects, breast-feeding success, or functional activity. Postoperative pain was generally well controlled. Adding valdecoxib after cesarean delivery under spinal anesthesia with intrathecal morphine is not supported at this time.     

Monitoring,prevention and treatment of side effects of long-acting neuraxial opioids for post-cesarean analgesia

Long-acting neuraxial opioids such as morphine and diamorphine, administered via spinal or epidural routes, are staple components of a multimodal approach to postoperative analgesia following cesarean delivery. The widespread use of neuraxial opioids is due largely to their significant analgesic efficacy and favorable safety profile. The most common side effects of neuraxial opioids are pruritus, nausea and vomiting. These symptoms appear to be dose-related. The most serious complication of neuraxial opioids is respiratory depression, which occurs in 0–0.9% of cases. Hypothermia has also been reported in association with neuraxial morphine use at cesarean delivery. This article will review recent advances in prophylaxis, treatment and monitoring of the side effects of long-acting neuraxial opioids.     

Quadratus lumborum block for postoperative analgesia after cesarean delivery: A systematic review with meta-analysis and trial-sequential analysis

Study objectiveThe aim of this study was to investigate the analgesic efficacy of Quadratus lumborum block (QLB) versus controls, transversus abdominis plane (TAP) block and neuraxial morphine, or when added to neuraxial morphine in women undergoing cesarean delivery.DesignSystematic review and meta-analysis with trial sequential analysis.PatientsParturients undergoing cesarean delivery.InterventionQuadratus lumborum block for postoperative analgesia.MeasurementsThe primary outcomes were dynamic and static pain scores and cumulative opioid consumption at 24 h. Secondary outcomes were dynamic and static pain scores and opioid consumption at 6 and 12 h. Certainty of evidence was assessed using the GRADE system. Trial sequential analyses (TSA) were performed to determine if the results are supported by sufficient data.Main resultsTen studies involving 761 parturients were included. Compared to controls, no difference in dynamic (MD -6; 95%CI -17 to 5) or static (MD -5; 95%CI -14 to 3) pain scores were noted with QLB at 24 h (moderate certainty), although opioid consumption (MD −10.64 mg morphine equivalents; −16.01 to −5.27) was reduced (high certainty), supported by sufficient data. QLB reduced dynamic pain at 6 h, and static pain and opioid consumption at 6 and 12 h compared to controls. Compared to neuraxial morphine, QLB did not alter opioid consumption or pain scores at 24 h (low certainty), although TSA suggests insufficient data. Due to limited data, meta-analysis and TSA were not performed to compare QLB and TAP blocks. Addition of QLB to neuraxial morphine did not alter dynamic and static pain scores at 24 h (moderate certainty, supported by sufficient data).ConclusionsQLB improves post-cesarean delivery analgesia in parturients not receiving neuraxial morphine. Addition of QLB to parturients receiving neuraxial morphine has no significant analgesic benefit. Insufficient data are available to draw firm conclusions of QLB compared to TAP blocks or neuraxial morphine.     

A randomized controlled trial examining the effect of naproxen on analgesia during the second day after cesarean delivery

Whereas nonsteroidal antiinflammatory drugs augment spinal morphine on Day l, the analgesia gained by simply combining these drugs with conventional "on request" oral regimens on Day 2 is less clear. In this trial, we randomized 80 women undergoing elective cesarean delivery with spinal morphine (0.2 mg) to receive naproxen (500 mg) or placebo every 12 h after surgery. Both groups received conventional therapy with acetaminophen with codeine (on request) and rescue IM opioids. Incision pain on sitting (IPS), incision pain at rest, uterine cramping, and gas pain were evaluated with visual analog scales (0-100). Worst interval pain (0-10), analgesic use, and side effects were measured over 72 h. At 36 h (primary outcome), naproxen use was associated with reductions in IPS (38.2 +/- 26.0 versus 51.4 +/- 25.7; P = 0.05), incision pain at rest, uterine cramping, and worst interval pain scores. Clinically modest, statistically significant reductions in IPS (P = 0.0001) and opioid use were found over time (P < 0.0l). Reductions in the incidence of inadequate analgesia and improvements in overall pain relief (P = 0.0006) on Day l did not persist on Day 2 (overall pain relief, P = 0.057; inadequate analgesia, 24% naproxen versus 27% controls; P = 1.00). The addition of regular doses of naproxen to conventional oral pain therapy after cesarean delivery leads to reductions in IPS at 36 h and pain over Day 2 but does not reduce the incidence of inadequate analgesia. IMPLICATIONS: This randomized trial suggests that adding regular doses of naproxen to conventional "on request" acetaminophen and codeine therapy provides small reductions in pain on the second day after cesarean delivery. The greatest effects occur at 36 h, when pain peaks.     

剖宫产术后多模式镇痛的研究进展

剖宫产术后疼痛程度可达中到重度，术后疼痛管理不到位可能对母儿造成多种短期和/或长期的不良后果，目前提倡采用多模式、个体化的镇痛管理方案，围绕产妇生理、心理、社会环境多方面，以保证剖宫产术后良好的镇痛效果，同时减少阿片类药物的应用，减轻阿片类药物相关不良反应，旨在加速产妇的康复，提高产妇总体满意度。本文对剖宫产术后疼痛评估及术后多模式镇痛的研究进展进行综述，为临床实践提供参考。     

Akutschmerztherapie in Orthopädie/Unfallchirurgie

The management of acute pain is of utmost importance in the treatment regimen of orthopedic and trauma patients. Pain perception is different for each patient and has to be individually addressed. Especially in a postoperative setting often with a very dynamic course of pain, it is optimal that the pain management is adapted to the individual course of pain. In this situation it makes sense to apply patient-controlled systems. By combining different analgesic substance classes and non-pharmaceutical therapy in the sense of a multimodal concept, the mechanisms of action complement each other and side effects can be reduced. Patient satisfaction is higher when they are actively involved in the (medicinal) pain therapy and in the decision making. This is particularly important for patient-controlled analgesia (PCA). In addition to invasive catheter administration procedures, there are also modern approaches for oral individual self-administered opioid treatment.     

Post-cesarean gabapentin is not associated with lower opioid consumption or pain scores in women on chronic buprenorphine therapy: A 10-year retrospective cohort study

Study objectiveTo determine if postoperative gabapentin administration is associated with decreased opioid consumption or pain scores following cesarean delivery in women on chronic buprenorphine.DesignRetrospective cohort study.SettingPostoperative recovery area and postpartum inpatient unit.Patients214 women undergoing cesarean delivery while on chronic buprenorphine at a single institution between 2007 and 2017.InterventionsGabapentin treatment for post-cesarean analgesia.MeasurementsThe primary outcome was opioid consumption in morphine milligram equivalents, comparing patients who received ≥1 dose of gabapentin within 24 h of cesarean delivery to those who did not. Secondary outcomes included opioid consumption 24–48 and 48–72 h post-cesarean and postoperative numerical rating scale pain scores.Main resultsOf 214 included patients, 64 (30%) received gabapentin while 150 (70%) did not. Gabapentin patients were more likely than controls to have received neuraxial fentanyl (30% vs. 14%, p = 0.01) and transversus abdominis plane block (6% vs. 1%, p = 0.05) and overall received higher doses of ketorolac and acetaminophen. Control patients were more likely to have received neuraxial morphine (78% vs. 90%, p = 0.04) and received higher doses of ibuprofen. In unadjusted analysis, there was no significant difference in morphine milligram equivalent consumption 0–24 h postoperatively between gabapentin (55 mg [IQR 26,84]) and control (53 mg [IQR 28,75]) groups (p = 0.38). After controlling for potential confounders, there remained no significant effect of gabapentin administration (overall effect p = 0.99). Opioid consumption and pain scores were also not significantly different at any other time points.ConclusionsIn parturients receiving chronic buprenorphine, inclusion of gabapentin in a multimodal analgesic regimen was not associated with lower opioid consumption or pain scores during the first 72 h after cesarean delivery. Prospective randomized studies are needed to confirm these findings.     

The elderly patient and postoperative pain treatment

The management of postoperative pain in elderly patients can be a difficult task. Older patients have co-existing diseases and concurrent medications, diminished functional status and physiological reserve and age-related pharmacodynamic and pharmacokinetic changes. Pain assessment presents numerous problems arising from differences in reporting cognitive impairment and difficulties in measurement. The elderly are also at higher risk of adverse consequences from surgery and unrelieved or undertreated pain. Selection of analgesic therapy needs to balance the potential efficacy with the incidence of interactions, complications or side effects in the post-operative period. Drug titration in the post-anaesthesia care unit should be encouraged together with analgesia on request in the wards. Multimodal analgesia, using acetaminophen, non-steroidal anti-inflammatory drugs or other non opioid drugs, is the best way to decrease opioid consumption and thus opioid-related adverse events. Sophisticated analgesic methods like PCA, regional analgesia and PCEA are not contraindicated in the elderly but pain relief and side effects should be monitored.     

Impact of timing of multimodal analgesia in enhanced recovery after cesarean delivery protocols on postoperative opioids: A single center before-and-after study

Study objectiveEnhanced recovery after cesarean delivery (ERAC) programs aim to decrease maternal morbidity and aid in maternal recovery and return to baseline. Multimodal analgesia is an important element of ERAC protocols, but no consensus exists on the timing of medication administration. We compared maternal pain outcomes following scheduled cesarean delivery with modification of the timing of administration of multimodal analgesia with non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen.DesignBefore-and-after study.SettingLabor and delivery unit at a single academic institution.InterventionNSAIDs and acetaminophen were administered as a fixed-interval alternating regimen every 3 h for the initial ERAC group (ERAC 1) and fixed-interval combined regimen every 6 h for the modified ERAC group (ERAC 2). ERAC 1 and ERAC 2 groups were compared to historical controls (Pre-ERAC).Patients520 women undergoing scheduled cesarean delivery (Pre-ERAC n = 179, ERAC 1 n = 179, and ERAC 2 n = 162).MeasurementsThe primary outcomes were postoperative total and daily opioid utilization as measured in morphine milligram equivalents (MME). Secondary outcomes included postoperative length of stay, maximum pain scores, and racial disparities in care.Main resultsThe modified schedule of non-opioid analgesics involving combined administration (ERAC 2) versus alternating administration (ERAC 1) of multimodal analgesia resulted in decreased total postoperative opioid utilization (median = 26.3 vs 52.5 MME, Bonferroni corrected P = 0.002). Total postoperative opioid utilization among the ERAC 2 group was also significantly reduced compared to the Pre-ERAC group (median = 26.3 vs 105.0 MME, Bonferroni corrected P < 0.0001).ConclusionsMultidisciplinary teams developing or modifying ERAC protocols for scheduled cesarean delivery should consider a combined administration at fixed intervals of NSAIDs and acetaminophen throughout the hospital stay to optimize postoperative pain management.     

Influence of anaesthetic and analgesic techniques on outcome after surgery

Postoperative symptoms and complications can be prevented bya suitable choice of anaesthetic and analgesic technique forspecific procedures. The aim of analgesic protocols is not onlyto reduce pain intensity but also to decrease the incidenceof side-effects from analgesic agents and to improve patientcomfort. Moreover, adequate pain control is a prerequisite forthe use of rehabilitation programmes to accelerate recoveryfrom surgery. Thus, combining opioid and/or non-opioid analgesicswith regional analgesic techniques not only improves analgesicefficacy but also reduces opioid demand and side-effects suchas nausea and vomiting, sedation, and prolongation of postoperativeileus. Although all attempts to demonstrate that regional anaesthesiaand analgesia decrease postoperative mortality are unsuccessful,there is evidence supporting a reduction in pulmonary complicationsafter major abdominal surgery, and an improvement in patientrehabilitation after orthopaedic surgery. When such techniquesare used, cost–benefit analysis should be considered todetermine suitable analgesic protocols for specific surgicalprocedures.     

Techniques of opioid administration

Opioids continue to be the main pharmacological treatment for severe acute pain. Traditional methods of opioid administration (oral, intramuscular, subcutaneous) are more effective in managing pain if the treatment regimens are individualized and dosages are titrated to effect (pain relief). Oxycodone, an opioid agonist similar in potency to morphine, has proved useful as an oral step-down analgesic in the treatment of acute postoperative pain for a number of surgical procedures (orthopaedic, abdominal, gynaecological). It is also a valuable alternative opioid to morphine intravenous patient-controlled analgesia (IV PCA) in those patients who experience severe unpleasant side effects, such as nausea and hallucinations. Other PCA modalities available for opioid administration in the treatment of acute pain include epidural and transmucosal (intranasal, sublingual, buccal). Transdermal delivery of highly lipid-soluble opioids is available for the treatment of severe pain in chronic and palliative care. This passive drug delivery system is not suitable for the routine management of severe acute pain because rapid and reliable changes to the delivery rate are not possible. However, advances in transdermal delivery system technology have led to the development of a non-invasive PCA system for the management of acute postoperative pain, which utilizes the process of iontophoresis. The fentanyl HCI iontophoretic transdermal system (fentanyl ITS) has the potential to be a valuable modality in the future management of acute postoperative pain.